10 December 2016

DnB Healthcare Prize 2016

Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.

Download

For the second year in a row, the DNB Healthcare Prize will be presented on the 15th of December during the the 7th annual DnB Healthcare Conference. The competition is for companies in an early growth phase.

The winner of the completion will be awarded NOK 1 million.

The companies selected for the DNB Healthcare Prize 2016 final competition include:

  1. SpinChip Diagnostics AS
  2. Vectron Biosolutions AS
  3. Otivio AS
  4. Prediktor Medical AS
  5. EpiGuard AS
  6. Oncoinvent AS

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.